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Introduction
Thrombolytic therapy is the only effective medication for 
the myocardial infarction (MI) and brain ischemic stroke, 
which are known as the leading causes of mortality and 
disability worldwide.1-6 The first thrombolytic agent was 
discovered in 1933,7 and then two thrombolytic therapies 
were reported in 1949 and 1950.8,9 
Numerous thrombolytic agents, comprising of 
streptokinase (EC: 3.4.24.29) and tissue plasminogen 
activator/s (tPAs; EC 3.4.21.68) have been introduced 
for the clinical uses, which may be categorized as 
different generations together with various agents, 
extracts, technologies and de novo advanced systems.7,10,11 
Bioactivity of a thrombolytic agent is not only an 
important parameter indicating its potential outcomes in 
experimental investigations, but also a vital measure for 
the clinical success in critical situations (e.g., cardiac or 
brain vascular interventions or thrombolytic therapies). 
Thrombolytic agents are usually enzymes whose 
functions may be affected by various factors, including 
pH, temperature, circumstance and time of maintenance. 
Such issues may influence the final clinical outcomes 
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Abstract
Introduction: Measurement of thrombolytic activity i.e. 
clot lysis is crucial for research and development of novel 
thrombolytics. It is also a key factor in assessment of the 
effectiveness of conventionally used thrombolytic agents 
in the clinic, which are the choice effective therapies for 
myocardial infarction and ischemic stroke. Previous 
methods used for the assessment of thrombolytic activity 
are often associated with some drawbacks such as being 
costly, time-consuming, complication and low accuracy. 
Here, we introduce a simple, economic, relatively 
accurate and fast method of spectrophotometric analysis 
of thrombolytic activity (SATA) assay, standardized 
by tissue plasminogen activator (tPA), which can 
quantitatively measure in vitro thrombolytic activity. 
Methods: Blood clots were formed, uniformly, by mixing citrated whole blood with partial 
thromboplastin time (PTT) reagent, together with calcium chloride. Then, designated concentrations 
of tPA were added to the samples, and the released red blood cells from each clot were quantified 
using spectrophotometry (λmax= 405 nm) as an indicator of thrombolytic activity. The accuracy of the 
method was tested by assessment of dose-responsibility against R2 value obtained by linear equation 
and measurement of limit of detection (LOD) and limit of quantification (LOQ). The SATA assay was 
validated in comparison with some currently used techniques. 
Results: A linear relationship was obtained between different concentrations of tPA versus the 
spectrophotometric absorbance of the related dilutions of lysed clots, at λmax = 405 nm. Calculated R2 
values were greater than 0.9; with LOD of 0.90 µg/mL of tPA (436.50IU) and LOQ of 2.99 µg/mL of 
tPA (1450.15IU). 
Conclusions: Conclusively, the SATA assay is a very simple quantitative method with repeatable and 
reproducible results for estimating the potency of an unknown thrombolytic agent, and calculating the 
activity as delicate as 1 µg/mL of tPA (485 IU/mL of thrombolytic dose).
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Persian Lab (Tehran, Iran), sterile water for injection 
and normal saline serum as diluent were obtained from 
the Iranian Parenteral and Pharmaceutical Company 
(Tehran, Iran). Insulin syringe was prepared from SUPA 
Medical Devices (Tehran, Iran). The activated partial 
thromboplastin time (APTT) reagent was purchased from 
the Pacific Hemostasis™ Fisher Scientific (Massachusetts, 
USA). Calcium chloride was acquired from Bahar Afshan 
(Tehran, Iran). The tissue plasminogen activator (tPA), 
Actilyse® (Alteplase), was bought from Boehringer 
Ingelheim (Ingelheim am Rhein, Germany).
Blood samples
Human whole blood was collected from cubital vein of 
adult volunteers by sterile venipuncture, transferred into 
buffered sodium citrate tubes and refrigerated until use. 
All volunteers were healthy, without current or previous 
hematologic, coagulative or bleeding disorders or recent 
abortion; they were not pregnant or on any hormonal 
therapy or contraception. The study was conducted as 
approved by the Ethics Committee of Tabriz University of 
Medical Sciences, and an informed consent was obtained 
from volunteers.
Production of blood clots 
Clots were formed using 300 µL of citrated whole blood 
mixed with 200 µL of PTT reagent and 200 µL CaCl2. Clot 
formation was completed in 5-10 minutes. For prevention 
of the spontaneous thrombolysis of clots, all reactions 
were performed on ice before conducting the SATA assay. 
Thrombolytic agent
Commercially available lyophilized tissue plasminogen 
activator (tPA) was used as the standard thrombolytic 
agent during SATA development. The vial was 
reconstituted with sterile water for injection as instructed 
by the manufacturer; hence the resulted solution of tPA (1 
mg/mL) was used as a stock. The stock was aliquoted and 
stored at -80°C until use. According to previous reports, 
reconstituted tPA preserves its activity for several months 
or a year at -30°C and for long-term (several years) at 
-80°C.29-32 Appropriate dilutions were prepared by mixing 
volumes of the stock with normal saline (N/S) as needed 
in the experiments. Dilutions were made freshly prior to 
the experiments and kept at 0-4°C during the experiments.
The tPA activity in terms of international units per 
nanogram (IU/ng) was also determined by active human 
tPA assay ELISA kit (Oxford Biomedical Research, 
Avon Industrial Park, Avon, MA, USA) following the 
manufacturer instruction. The assay incorporates 
plasminogen activator inhibitor-1 (PAI-1) specific for 
human tPA to capture active tPAs and an HRP conjugated 
secondary antibody for detection. Briefly, reconstituted 
biotinylated PAI-1 was added to 96 wells and the plate 
was shaken to ensure mixing. The wells were washed 
(3×) with wash buffer, and the standards and samples 
were added to the wells in duplicate, and the plate was 
of pharmacotherapy, especially during vital vascular 
interventions. 
Historically, in 1794, the phenomenon of fibrinolysis 
was introduced as “the blood-deprived of its coagulation 
power”.12 For the first time in the 1950s, euglobulin lysis 
assay was developed to measure the natural fibrinolysis.13-15 
Subsequently, a variety of methods were developed to 
measure the potency of thrombolytic agents for possible 
clinical administration. However, the methods in some 
cases appeared to be dependent on costly materials and 
agents. For instances, a relatively expensive D-dimer 
measurement was incorporated in the quantification of 
the fibrin degraded particles after lysis.16 Further, fibrin 
agarose plate assay (FAPA) needs fibrin, fibrinogen, and 
thrombin to be mixed with agarose.17-20 The occluded 
tube model needs thrombin to be mixed with the blood 
sample,21,22 and the heparin modulated clot lytic activity 
needs thrombin together with plasminogen.23 Moreover, 
the other un-official methods utilize thrombin.24,25 The 
time required for the assessment of thrombolytic enzymes’ 
activity is a very important factor in the case of emergency 
needs in the clinic. Thus, taken all, time is a limiting factor 
in these types of experiments.23,26,27 In a method, whole 
blood was recruited freshly and incubated at 37°C for 24 
hours to form clots spontaneously.28 Although the method 
is economic, it is rather time consuming and laborious, 
which makes it even more complicated to discriminate 
the spontaneous lysis of clot from lysing effect of the 
thrombolytic agent. The other problem in the previously 
developed methods is that the formed clots always are 
irregular along with some un-clotted residues that should 
be “aspirated out” or “washed with saline”.26,28 
In the present investigation, spectrophotometric 
analysis of thrombolytic activity (SATA) assay, that is 
actually designed for the measurement of clot lysis, was 
developed using partial thromboplastin time (PTT) 
reagent together with calcium chloride for the induction 
of a uniform and precisely equal clot formation. These 
reagents are inexpensive and easy to access, and when 
used properly, induce rapid (within several minutes) 
regular complete clots from plasma or whole blood 
samples. Here, this assay is introduced for the first time 
as a simple and non-expensive method for the analysis of 
thrombolytic activity in vitro, which could be performed 
in any laboratory equipped with a spectrophotometer, 
even in a hospital. The method has been established 
based on the UV/Vis absorbance of hemoglobin of red 
blood cells (RBCs) released from a clot; standardized by 
concentrations of standard tissue plasminogen activator 
(tPA). Performing the method by visualizing the red 
color, instead of the spectrophotometric absorbance of 
hemoglobin, makes it possible to have a rough estimate 
of the activity of thrombolytic drugs in a clinical setting. 
Materials and Methods
Materials and equipment
Buffered sodium citrated tube was purchased from 
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shaken again. Following, the plate was washed (3×) 
with wash buffer, and the primary antibody was added 
to the wells and the plate was shaken. Then, the wells 
were washed and the secondary antibody was included. 
Finally, 3,3′,5,5′-Tetramethylbenzidine (TMB) substrate 
was added and the plate was shaken for 2-10 minutes. The 
reaction was stopped by adding sulfuric acid, and the plate 
was read at 450 nm. All shakings were performed at 300 
rpm at room temperature for 30 minutes, except the last 
shaking which was for 2-10 minutes. 
The procedure of SATA assay
Designated dilutions (0, 0.5, 1, 2, 2.5, 5 and 7.5 µg/mL; 
equal to 0-3637.5 IU/mL) of tPA were prepared in normal 
saline. Then, 100 µL of each dilution was added to the clots 
in glass tubes and incubated at 37°C for different time 
periods for optimization of incubation (5-20 minutes). 
Then, 1 mL of normal saline was carefully added to 
the mixture (without destroying the residue clots) to 
suspend the liquid lysed clot containing RBCs carrying 
their hemoglobin. The suspension was diluted 25 times 
with normal saline and the absorbance of the suspension 
against the diluent blank was measured at the λmax of 405 
nm (the peak absorption of hemoglobin). Finally, the 
corresponding standard curve was plotted for different 
dilutions using corresponded optical densities.
Precision assessment of SATA assay
Thrombolytic activity based on the percentages of digested 
clot (% DC) was assessed,26 with some modifications 
during the procedure of blood clots production and 
preparation of dilutions and control sample. Standard 
dilutions (0-3637.5 IU/mL) of tPA were prepared, and 100 
µL of each dilution was added to the clots. The mixtures, 
in the labeled pre-weighed microtubes, were incubated 
at 37°C for 20 minutes. The weight of the primary clots 
and the residue clots after the clot lysis were measured 
and used to calculate the percentages of the digested clots 
(reduction in clot weight) according to the equation (1)26:
% 100Weight reductionof theclotDC
Weight of the primary clot
= ×              (Eq. 1)
 
Moreover, the occluded tube model was used for the 
analysis of the thrombolytic activity of tPA as reported 
previously.21,22 A transparent tube with a piston and 
internal diameter (ID) of 0.5 cm and length of 8 cm (an 
insulin syringe), was used for the model development. The 
mixture of citrated whole blood, CaCl2, and PTT reagent 
were added into the developed tube while the piston was 
in the middle, to form the clot in a fixed position along the 
tube. After completion of the clot formation, the piston 
was detached carefully and a clot which was formed 
homogenously without internal void volumes or loose 
adhesion inside the tube was used as a proper occluded 
tube model to mimic the clotting process in the blood 
vessels. One side of the occluded tube was filled with 
normal saline and the other side was filled with 300 µL 
of different concentrations of the thrombolytic agent. The 
two ends of the tube were properly sealed, and the tube 
was incubated at 37°C for different time periods. The 
appearance of a red color induced by the lysed clot at the 
clot surface exposed to normal saline was considered as 
the lysis time, while the recanalization time was measured 
in the case of formation of a visible channel along the clot. 
Troubleshooting and important hints
• When the suspension of the lysed clot is being diluted, 
the final volume should be set due to the volume 
needed to fill the cuvette of the spectrophotometer. 
• The dilutions of the suspension of the liquid lysed 
clot were adjusted so that the absorbance would be 
in the range (OD ~ 0.5 to 1.7). In the case of low/
high absorbance for any reason (e.g., modifications in 
the agent, concentrations, time, etc) dilutions would 
better be less/more, respectively.
• After the reconstitution of tPA, it is deactivated after 
several hours at room temperature and 24 hours 
at 4°C. Therefore, dilutions would better be made 
freshly prior to experiments and be kept at 4°C during 
the experiments.
• When the clots are formed, they show some 
spontaneous thrombolytic activity. To reduce 
spontaneous thrombolysis, clots should be kept on ice 
or refrigerator before and after the experiments. At the 
experimenting time, all clots with their thrombolytic 
agent should be incubated at 37°C, and taken from it 
at the same time.
• The differences of thrombolytic activity induced by 
various concentrations of tPA are rather insignificant 
during the first few minutes and also after long times 
when high concentrations of tPA have lysed the 
clots completely. The optimum time for finding the 
significant difference of concentrations in this range 
is 15-20 minutes. For continuance of the thrombolysis 
process for a longer period, the size of clots should be 
larger. 
• Clot formation by the current method should be 
completed without any residue. Also, the final 
volume of all clots (sum of whole blood and reagents) 
should be equal in different samples. In the case of 
incomplete clot formation, the quantity/quality of 
reagents should be checked. Moreover, the blood 
should be used during several days after collection, 
with normal coagulation (at least with normal 
international normalized ratio-INR) and mixed 
with a correct proportion of citrate. If necessary, the 
amount of reagents could be increased to complete 
the clot formation. However, it is recommended that 
other mentioned probable problems to be checked 
first. 
• Sterile water for injection could be used for the 
reconstitution of tPA, but not for the dilution or as 
the control versus the thrombolytic agents because 
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low osmolality destructs the clot without activating 
thrombolysis. Therefore, we used normal saline as the 
diluent in all steps (diluting thrombolytic agent or the 
lysed clot). 
• The clot residues are very delicate and could be 
disrupted easily, therefore the first dilution of the 
lysed clot must be done as gentle and fast as possible. 
Statistical analysis 
For statistical analysis, one-way analysis of variance 
(ANOVA) and independent Student’s t-test were applied 
to compare mean differences of ODs. A P value less than 
0.5 was considered statistically significant. 
Results
SATA assay
As thrombolysis continues, RBCs are released from the 
clot. The thrombolytic activity of various concentrations 
of tPA, in the range of 0-7.5 µg/mL (equal to 0-3637.5 IU/
mL), was measured by spectrophotometry of hemoglobin 
released from the lysing clot. A standard curve was plotted 
for the resulted absorbance values, and the equation 
together with R square value was calculated. The limit 
of detection (LOD) and limit of quantification (LOQ) of 
the method were calculated as well, and the results were 
compared with other methods previously introduced for 
the measurement of thrombolysis. The ODs obtained 
from clots lysed by tPA concentrations are presented in 
Fig. 1. 
A linear relationship was obtained between different 
concentrations of tPA and the spectrophotometric 
absorbance of the related dilutions of lysed clots, at λmax 
= 405 nm. Calculated R square values were more than 
0.9. LOD and LOQ are important characteristics in the 
method validation. They are used to describe the smallest 
concentration of an analyte that can be reliably measured 
by an analytical procedure.33 The mixture and absorption 
measurement of the lowest concentration of tPA were 
repeated at least 3 times. LOD and LOQ were calculated 
as follows:
3 SD of thelowest concentrationLOD
Slope of thecalibrationline
= ×
 
                                                                                       (Eq. 2)
10 SD of thelowest concentrationLOQ
Slope of thecalibrationline
= ×                                                                                        (Eq. 3)
As calculated for the SATA assay, the LOD was 0.90 
µg/mL of active tPA (436.50 IU) and LOQ 2.99 µg/mL of 
active tPA (1450.15 IU). The difference of optical densities 
induced by various concentrations of tPA was statistically 
significant (P < 0.05). The spectrophotometric absorbance 
at a spectrum of 190-700 nm for a dilution of lysed clot 
induced by one of the concentrations of tPA was obtained 
(Fig. 2). The mentioned linear relationship was in the 
corresponding wavelength (Fig. 2, peak no. 3) which 
is the peak absorption of hemoglobin. In addition, the 
differences in the red color of the diluted lysed clots could 
be visualized macroscopically, as shown in Fig. 3.
Precision assessment of SATA assay
To confirm the results obtained from the SATA assay, 
thrombolytic activity of different concentrations of tPA 
was also measured using conventional measurement of 
percent of digested clot. A linear relationship was obtained 
for different concentrations of active tPA plotted versus 
the related percentages of the digested clots. The standard 
curve of the percentages of digested clot is shown in Fig. 4. 
Although different concentrations of tPA caused different 
percentages of DC, these differences were not statistically 
significant. 
Besides, for further justification of effectiveness of the 
SATA assay, the occluded tube model was carried out as 
described previously.20,21 Fig. 5 shows different steps of 
the developed model. The model at the beginning of the 
Fig. 1. The optical density of clots lysed by different concentrations 
of tPA representative of their thrombolytic activity.
Fig. 2. Spectrum absorbance of a dilution of lysed clot induced by 
one of the concentrations of tPA.
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experiment is shown in Fig. 5A. Various concentrations of 
tPA could induce complete lysis of the occluding clot; even 
the control sample (normal saline free of tPA) induced 
complete lysis after nearly 4 hours (Fig. 5D). Table 1 shows 
the time of the clot lysis as well as the recanalization and 
complete lysis induced by various concentrations of tPA. 
The low concentrations of tPA, in the range of 0-10 µg/
mL (0-4850.00 IU), showed a clot lysis pattern similar to 
the control. Therefore, higher tPA concentrations were 
applied as 50, 150 and 200 µg/mL (24250, 72750 and 
97000 IU, respectively).
The activity of the standard concentrations of tPA was 
measured by the ELISA method (Fig. 6). The activity of 
the drug used in this investigation was about 0.485 IU/
ng, which was utilized for IUs calculation of the tPA used.
Discussion
Analysis of the thrombolytic activity of thrombolytic 
agents, that is actually a measurement of clot lysis, is 
crucial not only for the research but also for the clinical 
applications, including thrombolytic therapies for MI 
or ischemic stroke. Methods previously introduced for 
the measurement of thrombolytic activity appear to be 
associated with some limitations such as being costly, time-
consuming and complex and often with low accuracy. The 
measurement of thrombolytic activity by fibrin agarose 
plates have already been introduced however, it demands 
expensive materials and is not an exact quantitative 
analysis.19 The concentration of fibrin degraded particles 
released after clot lysis has been measured by D-dimer 
assay which is highly accurate, but it is an expensive 
approach.16 The occluded tube model, which simulates 
the obstruction of a vessel by a clot, was shown to be 
unable of discriminating the lower doses of thrombolytic 
agents while requiring expensive materials.21,22 Some 
economic methods have also been developed, including 
the measurement of percentage of digested clot26 and 
RBC release from tiny clots.28 These approaches are 
often inaccurate and time-consuming, while some other 
methods incorporate complex instruments or expensive 
agents.24,25,34 
The current investigation introduces the SATA 
assay, which provides a simple, economical, relatively 
accurate and fast method for quantitative analysis of 
the thrombolytic activity. The assay records the optical 
density (OD) of the dilutions of the lysed clot at 405 nm, 
by simple UV/Vis spectrophotometry. This wavelength is 
the peak absorption of the hemoglobin, and it could be a 
mean to detect the RBCs which are released from the clot, 
as thrombolysis continues. The SATA can be used both for 
estimation and comparison of the thrombolytic activities 
Fig. 3. Significant macroscopic differences of lysed clots by 
various concentrations of tPA. 
Fig. 5. The occluded tube model. Panels A, B, C, and D represent 
the starting point of the model, the initiation of clot lysis, the 
recanalization and completion of the thrombolysis process, 
respectively. 
Fig. 6. The activity of the standard concentrations of tPA measured 
by ELISA method. 
Fig. 4. Percentages of the digested clot by various concentrations 
of tPA representative of their thrombolytic activity. 
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as well as for quantification of the concentration of a 
standard thrombolytic agent (e.g., tPA, streptokinase and 
urokinase), which could induce similar thrombolysis as an 
unknown agent does. The resultant data from the SATA 
method showed that the equation calculated for the linear 
relationship of ODs versus tPA standard concentrations 
displayed a coefficient of determination greater than 0.9 
with precise discriminative LOD and LOQ values. These 
two values are used to describe the smallest concentration 
of analytes that can be reliably measured by an analytical 
procedure.33 In this investigation, the LOD and LOQ values 
were respectively 0.90 µg/mL and 2.99 µg/mL for active 
tPA ( 436.50 IU and 1450.15 IU, respectively). The current 
experiment was performed by 0-7.5 µg/mL of active tPA 
(0-3637.5 IU/mL). The discrimination power of SATA 
assay is well beyond the clinical dose of tPA infusion. For 
further comparison with other thrombolytic agents such 
as streptokinase, the IUs of thrombolytic agents could 
be used. Various potencies of commercial tPA have been 
reported as much as 1000-580000 IU/mg. The company 
which manufactured the tPA utilized in this experiment 
reported the potency of 580000 IU/mg; however, a study 
in 1990 reported the potency of marketed tPAs only about 
492000 IU/mg.35 The range of IUs discriminated in the 
current study is five times smaller than the range reported 
previously,26 whose model did not show any significant 
difference between three dilutions of streptokinase used. 
They only reported the difference between water as the 
negative control and dilutions of the thrombolytic agent. 
Similarly, we found no significant difference between 
percentages of the digested clots by various concentrations 
of active tPA. However similar to the SATA assay, the 
digested clot experiment could give a standard curve by 
linear correlation between the percentages of DC versus 
the concentrations of active tPA. However, the differences 
between results obtained by the minimum and maximum 
concentrations of active tPA is not significant regarding to 
the digested clot method (Fig. 4), while these differences 
appeared to be substantially significant in the developed 
SATA assay (Fig. 1), indicating the accuracy of data 
Table 1. Time points for the clot lysis, recanalization, and completion by various concentrations of tPA in the occluded tube model
tPA concentration (µg/mL) tPA activity (IU/mL) Clot lysis time (min) Re-canalization time (min) Complete lysis time (min)
Control (0) 0 36 70 ~180-240
50 24250 6 11 134
150 72750 3 11 70
200 97000 3 12 90
Table 2. Various methods for measurement of thrombolytic activity, advantages and disadvantages, a qualitative comparison
Method Cost Time consumption Complexity Accuracy Ref
SATA assay Low Low Low High Cuurent study
Percent of digested clot Low High Low Medium 26
Occlusive tube model Medium Medium Medium Low 21,22
RBC release from tiny clots Low High Low Medium 28
D-Dimer assessment High Unknown Medium Very high 23
Heparin modulated clot lytic activity Medium High High Unknown 16
ELISA High High High Very high Oxford Biomedical Research
Table 3. Various methods for measurement of thrombolytic activity in terms of time-effectiveness and accuracy, a quantitative comparison    
Method Time consumption (h) LOD, LOQ
respectively
Ref
SATA assay Precise: 3-4
Bedside estimate: <1 
0.90, 2.99 µg/mL tPA (436.50, 1450.15IU) Current study
Percent of digested clot Previously reported: ~ 6
Modified in this study: 2-3
Previously not reported
In this study: 25.02, 83.42 µg/mL tPA (12134.70, 40458.70 IU) 
26
Occluded tube model Previously not reported
In this study 4-8
Previously not reported
In this study > 50 µg/mL tPA (24250 IU)
21,22
RBC release from tiny clots > 24 Not reported 28
D-Dimer assessment > 6 103.5, 345 IU (calculated by the reported data) 16
ELISA 6-7 Reported 0.006 IU (0-1.77 ng/mL tPA) 
In this study: 0.008, 0.027 IU
Oxford 
Biomedical 
Research
Abbreviations: LOD, limit of detection; LOQ, limit of quantification.
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obtained by SATA in comparison with the digested clot 
method.
In addition to the fairly high quantitative and accuracy 
capacity, the SATA assay offers some other advantages as 
well. First, the clot formation in this assay is completed 
within several minutes, while in the other methods this step 
is somewhat time-consuming (4-24 hours).23,26,27 Second, 
the clot formation is literally completed without any 
residue, and the volume of the formed clot is predictable 
and manageable. Third, the SATA method incorporates 
citrated blood, which could be refrigerated for later use, 
while most of the other methods require fresh blood with 
its immediate natural clotting capacity.26,28 Overall, the 
experiment could be started and terminated at most in 
several hours. Based on these findings, the SATA assay 
appears to be an economical method that can be executed 
using inexpensive reagents and small amounts of the 
thrombolytic agent in low concentrations. 
Further, the SATA assay could discriminate very low 
concentrations of active tPA (<10 μg/mL), while the 
occluded tube model could differentiate the concentrations 
higher than 50 μg/mL. However, as a model simulating 
the in vivo vascular obstruction and recanalization, 
the occluded tube model reserves the value of farther 
translational interpretation of in vitro thrombolytic 
activities to clinical outcomes in thrombolytic therapies 
of MI or ischemic stroke. Ultimately, the measurement of 
tPA activity by ELISA was actually performed as the gold 
standard. ELISA method is extremely accurate and could 
discriminate active tPA concentrations as low as 0.01 ng/
mL. As instructed by the manufacturer of the ELISA kit, 
the standard concentrations were prepared according to 
IU/mL of tPA (i.e., 0-1 IU/mL equal to 0-1.77 ng/mL). 
Despite this high accuracy, there is no doubt that ELSA, 
especially for this purpose, possesses many limitations, 
including significant time consumption, high cost, 
complexity while many facilities are needed. Moreover, 
this method directly assesses the concentration of active 
enzymes and not an ultimate output of thrombolysis.
Historically, fibrinolysis was discovered through many 
observations including the fact that blood collected by 
wet-cupping (several milliliters) might be clotted and then 
spontaneously dissolved in 12-24 hours.36 Whole blood 
certainly possesses potency of lysing clot per se, and this 
potency originates from the natural blood thrombolytic 
agents. Thus, it is not of surprise that the control samples 
with zero concentration of active tPA exhibit clot lysis to 
some extents in all methods developed for thrombolytic 
activity measurement, including the developed SATA 
assay and the digested clot method. However, it is of 
wonder that, to the best of our knowledge, in the previously 
described methods spontaneous thrombolysis in control 
sample was rarely mentioned. 
Comparison of SATA with other methods developed 
previously is summarized in Table 2 and Table 3.
The SATA assay is a simple approach that can be 
performed for clarifying the tPA activity prior to clinical 
administration (bedside) in thrombolytic therapies 
of MI or ischemic stroke, by simple instruments and 
visualization of the difference of red color in dilutions even 
though with some degree of lower accuracy. However, 
such utility of the SATA assay in a clinical setting is just 
for further confirmation of thrombolytic activity of a 
drug with a rough estimation. Nevertheless, the SATA 
assay, if performed in hospital laboratories equipped 
with spectrophotometry, can provide a quite accurate 
thrombolytic activity value of clinically used drugs. 
Conclusion
The established SATA assay is a simple and cost-effective 
method with high precision and accuracy that can be 
conducted quantitatively and fast for in vitro measurement 
of thrombolytic agents’ activity. This method is able 
to discriminate less than 10 µg/mL of active tPA (4850 
IUs), which is thousands of times less than the clinical 
dose of tPA. The method could be used for comparing 
the thrombolytic activities of thrombolytic agents and 
measurement of the potency of unknown thrombolytic 
agents with some degree of high accuracy for investigations 
and clinical assessments. 
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